IP Library Granted Patent US 12,016,863
Granted Patent B2
US 12,016,863 · App. 17/052,595 · Granted Jun 25, 2024

Inhibitors of RSV replication and applications thereof

Inventors: Richard Plemper (Atlanta, GA); Julien Sourimant (Atlanta, GA); Edgars Jecs (Decatur, GA); Dennis Liotta (Atlanta, GA); Stephen Pelly (Atlanta, GA); Robert Wilson (Ganesvoort, NY); Zackery Will Dentmon (East Point, GA)
Assignees: Georgia State University Research Foundation, Inc.; Emory University
A61K31/519A61K31/353A61K47/60A61P31/14C07D311/16C07D311/18C07D487/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,016,863
App. No.
17/052,595
Granted
Jun 25, 2024
Kind
B2
Abstract

Disclosed herein are compounds having antiviral activity, and, in particular, an inhibitory activity on the replication of Respiratory Syncytial Virus (RSV). Druggable target sites, including Px, in the RSV N protein are disclosed, as well as compounds targeting Px. The compounds can be used to treat patients with RSV infection.

Claims (18)

1. A compound having the formula:

or a pharmaceutically acceptable salt thereof,

wherein:

X 1 is N;

X 2 is N;

Y is a phenyl group having the formula:

wherein R y2 , R y3 , R y4 , and R y5 are each hydrogen, and R y1 is selected from F, Cl, Br, I, and CF 3 ;

R 1 is hydrogen;

R 2 is selected C(O)OR 2a and C(O)N(R 2a ) 2 , wherein R 2a is in each case independently selected from , C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, aryl, C 1-8 heteroaryl, C 3-8 cycloalkyl, or C 1-8 heterocyclyl;

R 3 is hydrogen.

2. The compound according to claim 1 , wherein R y1 is CF 3 .

3. The compound according to claim 1 , wherein R 2 is C(O)OR 2a .

4. The compound according to claim 1 , wherein R 2 is C(O)OR 2a and R 2a is C 1-8 alkyl.

5. The compound according to claim 3 , wherein R y1 is Cl.

6. The compound according to claim 1 , wherein R y1 is F.

7. A pharmaceutical composition comprising the compound of claim 1 .

8. A method of treating a patient infected with RSV, comprising administering the compound of claim 1 .

9. The method of claim 8 , further comprising administering adjunctively at least one other active compound.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2024
From: PLEMPER, RICHARD; SOURIMANT, JULIEN
To: GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC.
Reel/Frame 066649/0168 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2024
From: JECS, EDGARS; LIOTTA, DENNIS; PELLY, STEPHEN; WILSON, ROBERT
To: EMORY UNIVERSITY
Reel/Frame 066649/0174 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2024
From: DENTMON, ZACKERY WILL
To: EMORY UNIVERSITY
Reel/Frame 066649/0181 →
CONFIRMATORY LICENSE Recorded Oct 26, 2023
From: GEORGIA STATE UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 065365/0297 →
Continuity (2)
Provisional Application 62666411 · May 3, 2018
Related Publication 20210244740A1 · Aug 12, 2021